Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Med Food ; 13(6): 1532-6, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20954802

RESUMEN

Chives have been used both as food and as medicine. Previously, two fibrinolytic enzymes, ATFE-I (90 kDa) and ATFE-II (55 kDa), were identified in chives (Allium tuberosum), a perennial herb. In the present work, ATFE-II was purified by ion-exchange chromatography followed by gel filtration. In addition, the enzyme properties of ATFE-I and ATFE-II were compared. The molecular mass and isoelectric point (pI value) of ATFE-II were 55 kDa and pI 4.0, respectively, as revealed using one- or two-dimensional fibrin zymography. ATFE-II was optimally active at pH 7.0 and 45°C. ATFE-II degraded the Aα-chain of human fibrinogen but did not hydrolyze the Bß-chain or the γ-chain, indicating that the enzyme is an α-fibrinogenase. The proteolytic activity of ATFE-II was completely inhibited by 1 mM leupeptin, indicating that the enzyme belongs to the cysteine protease class. ATFE-II was also inhibited by 1 mM Fe²(+). ATFE-II exhibited high specificity for MeO-Suc-Arg-Pro-Tyr-p-nitroaniline (S-2586), a synthetic chromogenic substrate of chymotrypsin. Thus proteolytic enzymes from A. tuberosum may be useful as thrombolytic agents.


Asunto(s)
Cebollino/enzimología , Cisteína Endopeptidasas , Descubrimiento de Drogas , Fibrinólisis , Fibrinolíticos , Componentes Aéreos de las Plantas/enzimología , Proteínas de Plantas , Cisteína Endopeptidasas/química , Cisteína Endopeptidasas/aislamiento & purificación , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/farmacología , Compuestos Ferrosos/farmacología , Fibrinógeno/metabolismo , Fibrinolíticos/química , Fibrinolíticos/aislamiento & purificación , Fibrinolíticos/metabolismo , Concentración de Iones de Hidrógeno , Hidrólisis , Punto Isoeléctrico , Isoenzimas/antagonistas & inhibidores , Isoenzimas/química , Isoenzimas/aislamiento & purificación , Isoenzimas/metabolismo , Leupeptinas/farmacología , Peso Molecular , Oligopéptidos/metabolismo , Proteínas de Plantas/antagonistas & inhibidores , Proteínas de Plantas/química , Proteínas de Plantas/aislamiento & purificación , Proteínas de Plantas/metabolismo , Especificidad por Sustrato , Temperatura , Terapia Trombolítica , Trombosis/tratamiento farmacológico
2.
J Microbiol Biotechnol ; 18(2): 263-9, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18309270

RESUMEN

Hydrazinocurcumin (HC), a synthetic derivative of curcumin, has been reported to inhibit angiogenesis via unknown mechanisms. Understanding the molecular mechanisms of the drug's action is important for the development of improved compounds with better pharmacological properties. A genomewide drug-induced haploinsufficiency screening of fission yeast gene deletion mutants has been applied to identify drug targets of HC. As a first step, the 50% inhibition concentration (IC50) of HC was determined to be 2.2 microM. The initial screening of 4,158 mutants in 384-well plates using robotics was performed at concentrations of 2, 3, and 4 microM. A second screening was performed to detect sensitivity to HC on the plates. The first screening revealed 178 candidates, and the second screening resulted in 13 candidates, following the elimination of 165 false positives. Final filtering of the condition-dependent haploinsufficient genes gave eight target genes. Analysis of the specific targets of HC has shown that they are related to septum formation and the general transcription processes, which may be related to histone acetyl transferase. The target mutants showed 65% growth inhibition in response to HC compared with wild-type controls, as shown by liquid culture assay.


Asunto(s)
Curcumina/análogos & derivados , Eliminación de Gen , Genoma Fúngico , Hidrazinas/farmacología , Proteínas de Schizosaccharomyces pombe/química , Schizosaccharomyces/efectos de los fármacos , Curcumina/farmacología , Evaluación Preclínica de Medicamentos , Haploidia , Heterocigoto , Concentración 50 Inhibidora , Schizosaccharomyces/genética , Schizosaccharomyces/crecimiento & desarrollo , Schizosaccharomyces/metabolismo , Proteínas de Schizosaccharomyces pombe/antagonistas & inhibidores , Proteínas de Schizosaccharomyces pombe/genética , Proteínas de Schizosaccharomyces pombe/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA